Section 4: Clinical Pharmacy Services

4CPS-166

IS THERE STILL A PLACE FOR CHLORAL HYDRATE SYRUP IN HOSPITAL?

4CPS-165

LIDOCAINE 5% PLASTER: IS IT WORTH THE PAIN?

4CPS-164

ORAL KETAMINE IN UNMANAGEABLE CHRONIC PAIN: A CASE REPORT

4CPS-163

BONE METASTASIS TREATMENT IN PROSTATE CANCER: EFFICACY AND SAFETY

4CPS-162

MEDICATION COUNSELLING BY CLINICAL PHARMACISTS IN NEWLY GRAFTED RENAL TRANSPLANT RECIPIENTS

4CPS-161

SCOPING REVIEW ON THE USE OF CANAKINUMAB AND ANAKINRA IN INTERLEUKIN-1 ANTAGONIST RECEPTOR DEFICIENCY

4CPS-160

EFFICACY AND SAFETY OF ANAKINRA AND CANAKINUMAB FOR THE TREATMENT OF IL-36R ANTAGONIST DEFICIENCY

4CPS-159

PERIOPERATIVE MANAGEMENT OF ANTIRHEUMATIC MEDICATION IN REAL PRACTICE: IS MISMANAGEMENT RELATED TO POST-SURGICAL COMPLICATIONS?

4CPS-158

CLINICAL BENEFIT OF INFLIXIMAB MONITORING IN INFLAMMATORY BOWEL DISEASE

4CPS-157

TUMOUR NECROSIS FACTOR INHIBITORS: UTILITY OF PHARMACOKINETICS MONITORING IN INFLAMMATORY BOWEL DISEASE MANAGEMENT

4CPS-156

SAFETY PROFILE OF APREMILAST IN PSORIASIS AND PSORIATIC ARTHRITIS

4CPS-155

A NEW MULTIDISCIPLINARY MODEL WITH THE CLINICAL PHARMACIST FOR MEDICATION RECONCILIATION IN THE PATIENT WITH ADVANCED RENAL DISEASE

4CPS-154

ABSTRACT WITHDRAWN

4CPS-153

COMPARATIVE ANALYSIS BETWEEN ORIGINATOR AND BIOSIMILAR INFLIXIMAB ACCORDING TO TROUGH LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

4CPS-152

CHEMOTHERAPY PHARMACEUTICAL CONSULTATION: PHARMACEUTICAL INTERVENTIONS AFTER 18 MONTHS OF IMPLEMENTATION

Pages